Cherry Creek Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Cherry Creek Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$382K	Sell	770 -562	-42%	-$249K	0.15%	83
2026 Q1	$595K	Sell	1,332 -68	-5%	-$31.7K	0.26%	58
2025 Q4	$635K	Sell	1,400 -722	-34%	-$311K	0.27%	57
2025 Q3	$831K	Sell	2,122 -986	-32%	-$412K	0.36%	44
2025 Q2	$1.38M	Sell	3,108 -71	-2%	-$32.7K	0.65%	34
2025 Q1	$1.54M	Hold	3,179	–	–	0.8%	30
2024 Q4	$1.28M	Sell	3,179 -143	-4%	-$66.3K	0.63%	32
2024 Q3	$1.54M	Hold	3,322	–	–	0.8%	28
2024 Q2	$1.56M	Buy	3,322 +493	+17%	+$214K	0.81%	28
2024 Q1	$1.18M	Buy	2,829 +1,816	+179%	+$768K	0.64%	32
2023 Q4	$412K	Buy	+1,013	New	+$374K	0.25%	61

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cherry Creek Investment Advisors's VRTX Position: Q2 2026 in Review

Cherry Creek Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q2 2026, selling an estimated $249K and leaving 770 shares worth $382K. The position accounts for 0.15% of the portfolio, ranked #83.

Cherry Creek Investment Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.56M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Cherry Creek Investment Advisors held 770 shares of Vertex Pharmaceuticals worth $382K as of Q2 2026.
Cherry Creek Investment Advisors sold 562 Vertex Pharmaceuticals shares in Q2 2026, an estimated $249K.
Vertex Pharmaceuticals made up 0.15% of Cherry Creek Investment Advisors's portfolio in Q2 2026, its #83 holding.
Cherry Creek Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Cherry Creek Investment Advisors's Vertex Pharmaceuticals position peaked at $1.56M in Q2 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cherry Creek Investment Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.